StockData
ImmuCell Corp logo

ImmuCell Corp (ICCC) stock

ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/302% above fair value
$11.17−0.08 (-0.71%)

Close on Nov 19, 2026Market cap $101.45MP/E 139.6Yield –

ImmuCell free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

ImmuCell's free cash flow for the twelve months ending Jun 30, 2026 was $4.21M, up 138.9% year over year. For fiscal 2025 it was $1.22M. Over ten years it grew 21.1% a year on average. The highest annual figure on record is $1.22M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.22M–
FY2024Dec 31, 2024-$107.82K–
FY2023Dec 31, 2023-$6.57M–
FY2022Dec 31, 2022-$5.52M–
FY2021Dec 31, 2021-$1.65M–
FY2020Dec 31, 2020-$2.76M–
FY2019Dec 31, 2019-$1.16M–
FY2018Dec 31, 2018-$2.40M–
FY2017Dec 31, 2017-$16.58M–
FY2016Dec 31, 2016-$3.81M-2203.7%
FY2015Dec 31, 2015$181.05K–
FY2014Dec 31, 2014-$1.23M-346.2%
FY2013Dec 31, 2013$500.96K+626.1%
FY2012Dec 31, 2012$69.00K–
FY2011Dec 31, 2011-$281.05K–
FY2010Dec 31, 2010-$925.16K–
FY2009Dec 31, 2009-$569.21K–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.29M+58.0%
Q1 FY2026Mar 31, 2026$3.40M+172.8%
Q4 FY2025Dec 31, 2025$310.24K–
Q3 FY2025Sep 30, 2025-$1.78M–
Q2 FY2025Jun 30, 2025$1.45M+207.1%
Q1 FY2025Mar 31, 2025$1.24M+257.5%
Q4 FY2024Dec 31, 2024-$199.27K–
Q3 FY2024Sep 30, 2024-$727.74K–
Q2 FY2024Jun 30, 2024$471.04K–
Q1 FY2024Mar 31, 2024$348.15K–
Q4 FY2023Dec 31, 2023-$804.42K–
Q3 FY2023Sep 30, 2023-$928.27K–
Q2 FY2023Jun 30, 2023-$1.39M–
Q1 FY2023Mar 31, 2023-$3.44M–
Q4 FY2022Dec 31, 2022-$2.79M–
Q3 FY2022Sep 30, 2022-$1.99M–
Q2 FY2022Jun 30, 2022-$569.83K–
Q1 FY2022Mar 31, 2022-$168.96K–
Q4 FY2021Dec 31, 2021-$116.70K–
Q3 FY2021Sep 30, 2021-$416.41K–
Q2 FY2021Jun 30, 2021-$148.51K–
Q1 FY2021Mar 31, 2021-$972.86K–
Q4 FY2020Dec 31, 2020-$128.43K–
Q3 FY2020Sep 30, 2020-$2.14M–
Q2 FY2020Jun 30, 2020-$93.39K–
Q1 FY2020Mar 31, 2020-$394.69K-181.8%
Q4 FY2019Dec 31, 2019-$738.05K–
Q3 FY2019Sep 30, 2019-$466.29K–
Q2 FY2019Jun 30, 2019-$436.39K–
Q1 FY2019Mar 31, 2019$482.79K–
Q4 FY2018Dec 31, 2018-$237.10K–
Q3 FY2018Sep 30, 2018-$721.90K–
Q2 FY2018Jun 30, 2018-$480.71K–
Q1 FY2018Mar 31, 2018-$963.59K–
Q4 FY2017Dec 31, 2017-$4.35M–
Q3 FY2017Sep 30, 2017-$4.72M–
Q2 FY2017Jun 30, 2017-$3.84M–
Q1 FY2017Mar 31, 2017-$3.68M–
Q4 FY2016Dec 31, 2016-$2.16M–
Q3 FY2016Sep 30, 2016-$1.12M–

More ImmuCell figures

See a number that looks wrong?